✦ LIBER ✦

Aktivation of the Akt and MAPK pathways in relation to survival for patients with estrogen receptor positive breast cancer subjected to adjuvant tamoxifen

✍ Scribed by B. Linderholm; P. Karlsson; M. Sundqvist; L.G. Arnesson; B. Nordenskjold; O. Stal

Book ID: 119597822
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 55 KB
Volume: 6
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(08)70328-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Obesity enhances nongenomic estrogen rec

Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promotein vitromeasures of breast cancer progression

✍ Bowers, Laura W; Cavazos, David A; Maximo, Ilane XF; Brenner, Andrew J; Hursting 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 438 KB

Concordance and discordance of estrogen

Concordance and discordance of estrogen and progesterone receptor content in sequential biopsies of patients with advanced breast cancer: Relation to survival

✍ John M Raemaekers; Loek V Beex; Anthony J Koenders; Gerlach F Pieters; Anthony G 📂 Article 📅 1984 🏛 Elsevier Science ⚖ 754 KB

Adjuvant therapy with GnRH agonists/tamo

Adjuvant therapy with GnRH agonists/tamoxifen in breast cancer should be a good council for patients with hormone receptor-positive tumours and wish to preserve fertility

✍ J.G. Franco Jr; J.B.A. Oliveira; C.G. Petersen; A.L. Mauri; R. Baruffi; M. Cavag 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 144 KB

RELATION BETWEEN IMMUNOCYTOCHEMICAL ESTI

RELATION BETWEEN IMMUNOCYTOCHEMICAL ESTIMATION OF OESTROGEN RECEPTOR IN ELDERLY PATIENTS WITH PRIMARY BREAST CANCER AND RESPONSE TO TAMOXIFEN

✍ Gaskell, D.J; Sangsterl, K; Hawkins, R.A; Chetty, U; Forrest, A.P.M 📂 Article 📅 1989 🏛 The Lancet 🌐 English ⚖ 460 KB

Randomized adjuvant trial to evaluate th

Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5-year results from the nishi-nippon group of the adjuvant chemoendocrine therapy for breast cancer organization

✍ Masakazu Toil; Takao Hattori; Masanobu Akagi; Kiyoshi Lnokuchi; Kunzo Orita; Kei 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 714 KB

Background. A randomized adjuvant trial was conducted from October 1982 to January 1985 to evaluate the addition of tamoxifen (TAM) to combination chemotherapy with perioperative mitomycin C (MMC) and ftorafur (FT) for patients with estrogen receptor (ER)-positive tumors and the addition of PSK, a b

The utility of estrogen receptor, proges

The utility of estrogen receptor, progesterone receptor, and Her-2/neu status to predict survival in patients undergoing hepatic resection for breast cancer metastases

✍ Steve R. Martinez; Shawn E. Young; Armando E. Giuliano; Anton J. Bilchik 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 61 KB